WEIGHT LOSS SPECIALIST – DHA LAHORE
Dual-action GLP-1 & GIP injection for medically supervised weight management – prescribed after full evaluation in DHA Lahore.
ماؤنجارو (Tirzepatide) ایک جدید انجیکشن ہے جو بھوک کو کم کرتا ہے اور وزن کو مؤثر طریقے سے گھٹاتا ہے۔ یہ ہفتے میں ایک بار لگایا جاتا ہے اور ڈاکٹر رضوان نیازی کی نگرانی میں تجویز کیا جاتا ہے۔
Mounjaro is a dual GLP-1 and GIP receptor agonist – the first of its kind approved for weight management. By activating two separate hormonal pathways simultaneously, it delivers significantly greater weight reduction than single-receptor injections.
Clinical trials show an average of 25–29% body weight reduction over 72–88 weeks – the highest of any available weight loss injection. It also improves blood sugar, blood pressure, and metabolic markers.
Tirzepatide activates both GLP-1 and GIP receptors – two hormones that control appetite, digestion, and blood sugar.
Reduces appetite, slows gastric emptying, and improves insulin secretion – helping you eat less and feel full longer.
Works alongside GLP-1 to enhance fat burning and improve how the body uses insulin – a dual-action advantage.
Beyond weight loss: improves HbA1c, reduces blood pressure, and lowers cardiovascular risk markers.
Mounjaro is well-studied and FDA-approved. Like all medications, it has potential side effects and requires medical supervision.
Nausea, vomiting, diarrhoea, and reduced appetite – most common in the first few weeks and usually improve with dose titration.
Not recommended for patients with personal or family history of medullary thyroid cancer, MEN2, or pancreatitis. Requires full medical assessment.
When properly prescribed, dose-titrated, and monitored, Mounjaro is safe and well-tolerated in suitable patients.
Book a consultation with Dr. Rizwan Niazi for a full evaluation and personalised prescription plan.
Dr. Rizwan also prescribes the following injections based on individual patient assessment.
ⓘ All injections are prescribed based on individual assessment under proper medical supervision.
Mounjaro must never be self-prescribed. A full clinical assessment determines your suitability, correct dose, and monitoring schedule to ensure safe and effective results.
Dr. Rizwan reviews your BMI, medical history, medications, and metabolic markers before prescribing.
Dose adjustments and progress reviews are scheduled to track results and manage any side effects.
Blood tests confirm metabolic response and rule out any contraindications during treatment.
The right injection depends on your weight, medical history, blood sugar levels, and treatment goals. Dr. Rizwan will recommend the most suitable option after a full evaluation.
Mounjaro (Tirzepatide) is a dual GLP-1 and GIP receptor agonist. It reduces appetite, slows digestion, and improves insulin sensitivity – resulting in significant, sustained weight loss.
Clinical trials show an average of 25–29% body weight reduction over 72–88 weeks. Individual results depend on dose, diet, lifestyle, and medical history.
Yes. Mounjaro is available in Pakistan and can be prescribed by a qualified specialist. Dr. Rizwan Niazi prescribes it after a full clinical assessment at his clinic in DHA Lahore.
Mounjaro is a once-weekly subcutaneous injection. The dose is typically started at 2.5 mg/week and gradually increased based on tolerance and response.
The most common side effects are nausea, vomiting, diarrhoea, and reduced appetite – especially during the first few weeks. These usually improve as the body adjusts to the medication.
No. Mounjaro is a prescription medication and must only be used under direct medical supervision. Self-administration without assessment is unsafe and not recommended.